Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Venous Thrombosis

  Free Subscription


Articles published in Thromb Haemost

Retrieve available abstracts of 116 articles:
HTML format
Text format



Single Articles


    April 2018
  1. BAUERSACHS R, Lee AYY, Kamphuisen PW, Meyer G, et al
    Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641150.
    PubMed     Text format     Abstract available


  2. BOURGUIGNON T, Bernard A, Fauchier L
    Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis.
    Thromb Haemost. 2018 Apr 4. doi: 10.1055/s-0038-1641167.
    PubMed     Text format    


  3. HUGON-RODIN J, Horellou MH, Conard J, Gompel A, et al
    Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
    Thromb Haemost. 2018 Apr 3. doi: 10.1055/s-0038-1641152.
    PubMed     Text format     Abstract available


  4. GOLDMAN S, Fraczek P, Szklanny K, Papuga-Szela E, et al
    Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
    Thromb Haemost. 2018;118:654-663.
    PubMed     Text format     Abstract available


    March 2018
  5. KHORANA AA, Weitz JI
    Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Thromb Haemost. 2018 Mar 22. doi: 10.1160/TH17-09-0681.
    PubMed     Text format     Abstract available


  6. CAMM AJ
    The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Thromb Haemost. 2018 Mar 22. doi: 10.1055/s-0038-1632387.
    PubMed     Text format     Abstract available


  7. BARBERO E, Bikdeli B, Chiluiza D, Barrios D, et al
    Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism.
    Thromb Haemost. 2018 Mar 19. doi: 10.1055/s-0038-1637746.
    PubMed     Text format    


  8. LEHNERT P, Lange T, Moller CH, Olsen PS, et al
    Acute Pulmonary Embolism in a National Danish Cohort: Increasing Incidence and Decreasing Mortality.
    Thromb Haemost. 2018;118:539-546.
    PubMed     Text format     Abstract available


    February 2018
  9. LUTSEY PL, Horvath KJ, Fullam L, Moll S, et al
    Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1625985.
    PubMed     Text format     Abstract available


  10. MARTOS L, Ramon LA, Oto J, Fernandez-Pardo A, et al
    alpha2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:alpha2M Levels Are Associated with Venous Thromboembolism.
    Thromb Haemost. 2018 Feb 15. doi: 10.1055/s-0038-1629902.
    PubMed     Text format     Abstract available


  11. VAN DER POL LM, van der Hulle T, Mairuhu ATA, Huisman MV, et al
    Combination of Pulmonary Embolism Rule-out Criteria and YEARS Algorithm in a European Cohort of Patients with Suspected Pulmonary Embolism.
    Thromb Haemost. 2018 Feb 1. doi: 10.1055/s-0038-1623535.
    PubMed     Text format     Abstract available


  12. SPRONK HMH, Padro T, Siland JE, Prochaska JH, et al
    Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
    Thromb Haemost. 2018;118:229-250.
    PubMed     Text format     Abstract available


    January 2018
  13. BIKDELI B, Jimenez D, Hawkins M, Ortiz S, et al
    Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).
    Thromb Haemost. 2018;118:214-224.
    PubMed     Text format     Abstract available


  14. BLONDON M, Spirk D, Kucher N, Aujesky D, et al
    Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients.
    Thromb Haemost. 2018;118:82-89.
    PubMed     Text format     Abstract available


    December 2017
  15. KLOK FA, Ageno W, Barco S, Binder H, et al
    Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
    Thromb Haemost. 2017;117:2425-2434.
    PubMed     Text format    


  16. MEDINA A, Raskob G, Ageno W, Cohen AT, et al
    Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Thromb Haemost. 2017;117:2406-2414.
    PubMed     Text format    


  17. RAUZI F, Smyth E, Emerson M
    Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.
    Thromb Haemost. 2017;117:2283-2290.
    PubMed     Text format    


  18. BYKOV K, Bohn RL, Ewenstein BM, Seeger JD, et al
    Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
    Thromb Haemost. 2017;117:2267-2273.
    PubMed     Text format    


  19. LEE LH, Gallus A, Jindal R, Wang C, et al
    Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review.
    Thromb Haemost. 2017;117:2243-2260.
    PubMed     Text format    


    November 2017
  20. HALTON JML, Picard AC, Harper R, Huang F, et al
    Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Thromb Haemost. 2017;117:2168-2175.
    PubMed     Text format     Abstract available


  21. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117:2163-2167.
    PubMed     Text format     Abstract available


  22. KHORANA AA, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117:2135-2145.
    PubMed     Text format     Abstract available


  23. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117:2045-2052.
    PubMed     Text format     Abstract available


    October 2017
  24. BASS AR, Fields KG, Goto R, Turissini G, et al
    Clinical Decision Rules for Pulmonary Embolism in Hospitalized Patients: A Systematic Literature Review and Meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  25. VAN OMMEN CH, Klaassen ILM, van Els AL, van de Wetering MD, et al
    Increasing Incidence and Recurrence Rate of Venous Thromboembolism in Paediatric Oncology Patients in One Single Centre Over 25 Years.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  26. GOLDHABER SZ, Schulman S, Eriksson H, Feuring M, et al
    Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  27. DEN EXTER PL, Hooijer J, van der Hulle T, van Oosten JP, et al
    Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


    September 2017
  28. KHORANA A, Vadhan-Raj S, Kuderer NM, Wun T, et al
    Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  29. SCHULMAN S
    Accumulating data on rivaroxaban for venous thromboembolism in clinical practice.
    Thromb Haemost. 2017;117.
    PubMed     Text format    


    August 2017
  30. SEILER E, Limacher A, Mean M, Beer HJ, et al
    Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  31. MCBANE RD, Loprinzi CL, Ashrani A, Perez-Botero J, et al
    Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  32. BLEKER SM, Brekelmans MPA, Eerenberg ES, Cohen AT, et al
    Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  33. TAKACH LAPNER S, Julian JA, Linkins LA, Bates S, et al
    Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  34. JANION-SADOWSKA A, Natorska J, Siudut J, Zabczyk M, et al
    Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


    June 2017
  35. COLEMAN CI, Coleman C, Bunz TJ, Turpie AGG, et al
    Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


  36. SCHULMAN S, Ageno W, Konstantinides SV
    Venous thromboembolism: Past, present and future.
    Thromb Haemost. 2017;117:1219-1229.
    PubMed     Text format     Abstract available


  37. VAN DER HULLE T, van Es N, den Exter P, van Es J, et al
    Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis.
    Thromb Haemost. 2017;117.
    PubMed     Text format     Abstract available


    May 2017
  38. CHUNG WS, Lin CL
    Increased risks of venous thromboembolism in patients with psoriasis. A Nationwide Cohort Study.
    Thromb Haemost. 2017 May 24. doi: 10.1160/TH17-01-0039.
    PubMed     Text format     Abstract available


    April 2017
  39. SANTI RM, Ceccarelli M, Bernocco E, Monagheddu C, et al
    Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
    Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895.
    PubMed     Text format     Abstract available


  40. SCHULMAN S, Singer D, Ageno W, Casella IB, et al
    NOACs for treatment of venous thromboembolism in clinical practice.
    Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH17-01-0065.
    PubMed     Text format     Abstract available


  41. COHEN AT, Gitt AK, Bauersachs R, Fronk EM, et al
    The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Thromb Haemost. 2017 Apr 13. doi: 10.1160/TH16-10-0793.
    PubMed     Text format     Abstract available


    March 2017
  42. RAJPURKAR M, Biss T, Amankwah E, Martinez D, et al
    Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
    Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-07-0529.
    PubMed     Text format     Abstract available


  43. SINDET-PEDERSEN C, Langtved Pallisgaard J, Staerk L, Gerds TA, et al
    Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
    Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-10-0745.
    PubMed     Text format     Abstract available


  44. TAFUR AJ, Caprini JA, Cote L, Trujillo-Santos J, et al
    Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0840.
    PubMed     Text format     Abstract available


  45. KLOK FA, Barco S, Konstantinides SV
    External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-10-0810.
    PubMed     Text format     Abstract available


    February 2017

  46. Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
    Thromb Haemost. 2017;117:643.
    PubMed     Text format    


  47. DENTALI F, Mumoli N, Prisco D, Fontanella A, et al
    Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
    Thromb Haemost. 2017;117:606-617.
    PubMed     Text format     Abstract available


  48. DING Q, Yang L, Zhao X, Wu W, et al
    Paradoxical bleeding and thrombotic episodes of dysprothrombinaemia due to a homozygous Arg382His mutation.
    Thromb Haemost. 2017;117:479-490.
    PubMed     Text format     Abstract available


  49. HEIT JA, Armasu SM, McCauley BM, Kullo IJ, et al
    Identification of unique venous thromboembolism-susceptibility variants in African-Americans.
    Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652.
    PubMed     Text format     Abstract available


  50. BREKELMANS MP, Scheres LJ, Bleker SM, Hutten BA, et al
    Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Thromb Haemost. 2017 Feb 9. doi: 10.1160/TH16-11-0874.
    PubMed     Text format     Abstract available


  51. STUCK AK, Spirk D, Schaudt J, Kucher N, et al
    Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-08-0631.
    PubMed     Text format     Abstract available


  52. BOCHENEK ML, Rosinus NS, Lankeit M, Hobohm L, et al
    From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0790.
    PubMed     Text format     Abstract available


    January 2017
  53. CHAI-ADISAKSOPHA C, Linkins LA, ALKindi SY, Cheah M, et al
    Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Thromb Haemost. 2017 Jan 12. doi: 10.1160/TH16-09-0680.
    PubMed     Text format     Abstract available


  54. ZHAO B, Zhang Y, Huang Y, Yu J, et al
    A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Thromb Haemost. 2017;117:44-56.
    PubMed     Text format     Abstract available


    December 2016
  55. HEIT JA, Ashrani A, Crusan DJ, McBane RD, et al
    Reasons for the persistent incidence of venous thromboembolism.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


    November 2016
  56. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
    Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  57. AY C, Pabinger I, Cohen AT
    Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  58. AGENO W, Casella I, Han CK, Raskob GE, et al
    RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


    October 2016
  59. TRUJILLO-SANTOS J, Di Micco P, Dentali F, Douketis J, et al
    Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  60. RIEDL J, Kaider A, Marosi C, Prager GW, et al
    Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available


  61. AMBROSINO P, Tarantino L, Di Minno G, Paternoster M, et al
    The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available



  62. Venous thromboembolism: A Call for risk assessment in all hospitalised patients.
    Thromb Haemost. 2016;116:777-779.
    PubMed     Text format    


  63. COHEN AT, Katholing A, Rietbrock S, Bamber L, et al
    Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available


    September 2016

  64. Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
    Thromb Haemost. 2016;116:775.
    PubMed     Text format     Abstract available


  65. WEITZ JI, Haas S, Ageno W, Angchaisuksiri P, et al
    Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  66. CAPPATO R, Welsh R
    Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  67. BLEKER SM, Cohen AT, Buller HR, Agnelli G, et al
    Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    August 2016
  68. DI NISIO M, Vedovati MC, Riera-Mestre A, Prins MH, et al
    Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    July 2016
  69. DELLUC A, Tromeur C, Le Ven F, Gouillou M, et al
    Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  70. VERHAMME P, Wells PS, Segers A, Ageno W, et al
    Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  71. ROLDAN V, Marin F
    Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention.
    Thromb Haemost. 2016;116.
    PubMed     Text format    


  72. GOLDHABER SZ, Schellong S, Kakkar A, Eriksson H, et al
    Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  73. AMBROSINO P, Tarantino L, Criscuolo L, Nasto A, et al
    The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  74. NAGLER M, Kremer Hovinga JA, Alberio L, Peter-Salonen K, et al
    Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    June 2016
  75. LUBBERTS B, Paulino Pereira NR, Kabrhel C, Kuter DJ, et al
    What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  76. KUCHER N, Aujesky D, Beer JH, Mazzolai L, et al
    Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  77. KITTELSON JM, Steg PG, Halperin JL, Goldenberg NA, et al
    Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  78. CROUS-BOU M, De Vivo I, Camargo CA Jr, Varraso R, et al
    Interactions of established risk factors and a GWAS-based genetic risk score on the risk of venous thromboembolism.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  79. AHMAD A, Sundquist K, Zoller B, Dahlback B, et al
    Identification of polymorphisms in Apolipoprotein M gene and their relationship with risk of recurrent venous thromboembolism.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  80. LARSEN TB, Skjoth F, Grove EL, Nielsen PB, et al
    Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. A propensity-matched cohort study.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    April 2016
  81. MANCO-JOHNSON MJ, Bomgaars L, Palascak J, Shapiro A, et al
    Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    March 2016
  82. BARCO S, Lankeit M, Binder H, Schellong S, et al
    Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  83. WANG MT, Liou JT, Huang YW, Lin CW, et al
    Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


    February 2016
  84. PHILIPPART R, Brunet-Bernard A, Clementy N, Bourguignon T, et al
    Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


  85. WONG CC, Ng AC, Lau JK, Chow V, et al
    High mortality in patients presenting with acute pulmonary embolism and elevated INR not on anticoagulant therapy.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


    January 2016
  86. JIMENEZ D, Lobo JL, Fernandez-Golfin C, Portillo AK, et al
    Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


  87. POSCH F, Riedl J, Reitter EM, Kaider A, et al
    Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


    December 2015
  88. RASKOB GE, Gallus AS, Sanders P, Thompson JR, et al
    Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  89. BRATEANU A, Patel K, Chagin K, Tunsupon P, et al
    Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  90. KONSTANTINIDES SV
    Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?
    Thromb Haemost. 2015;115.
    PubMed     Text format    


    November 2015
  91. BARCO S, Woersching AL, Spyropoulos AC, Piovella F, et al
    European Union-28: An annualised cost-of-illness model for venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  92. ANDRO M, Delluc A, Moineau MP, Tromeur C, et al
    Serum levels of 25(OH)D are not associated with venous thromboembolism in the elderly population. A case-control study.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


    October 2015
  93. DI NISIO M, Ageno W, Rutjes AW, Pap AF, et al
    Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  94. ENGSTROM G, Zoller B, Svensson PJ, Melander O, et al
    Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  95. LIU X, Thompson J, Phatak H, Mardekian J, et al
    Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  96. CUNHA ML, Meijers JC, Middeldorp S
    Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


    September 2015
  97. MAJEED A, Goldhaber SZ, Kakkar A, Kearon C, et al
    Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  98. DENTALI F, Ageno W, Pomero F, Fenoglio L, et al
    Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  99. LIN JN, Chen HJ, Lin MC, Lai CH, et al
    Risk of venous thromboembolism in patients with splenic injury and splenectomy. A nationwide cohort study.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


    August 2015
  100. IANOTTO JC, Chauveau A, Luque Paz D, Delluc A, et al
    Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format    


  101. SUCHON P, Al Frouh F, Henneuse A, Ibrahim M, et al
    Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic Risk Monitoring (PILGRIM) Study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  102. CHUNG WS, Lin CL, Kao CH
    Diabetesincreases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  103. VAN ES N, Di Nisio M, Bleker SM, Segers A, et al
    Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  104. ZOLLER B, Li X, Ohlsson H, Ji J, et al
    Family history of venous thromboembolism as a risk factor and genetic research tool.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  105. CUGNO M, Marzano AV, Bucciarelli P, Balice Y, et al
    Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


    July 2015
  106. KOOISTRA HA, Gebel M, Sahin K, Lensing AW, et al
    Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  107. TANG L, Hu Y
    Ethnic diversity in the genetics of venous thromboembolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


    June 2015
  108. BLACK SA, Cohen AT
    Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  109. HILLIS C, Crowther MA
    Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Thromb Haemost. 2015;113:1193-202.
    PubMed     Text format     Abstract available


  110. GRANZIERA S, Cohen AT
    VTE primary prevention, including hospitalised medical and orthopaedic surgical patients.
    Thromb Haemost. 2015;113:1216-23.
    PubMed     Text format     Abstract available


  111. PRANDONI P, Barbar S, Milan M, Campello E, et al
    Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Thromb Haemost. 2015;113:1210-5.
    PubMed     Text format     Abstract available


    May 2015
  112. CHAI-ADISAKSOPHA C, Hillis C, Monreal M, Witt DM, et al
    Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  113. DEN EXTER PL, van Es J, Kroft LJ, Erkens PM, et al
    Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  114. LIPPI G, Mattiuzzi C, Franchini M
    Sleep apnea and venous thromboembolism. A systematic review.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  115. WEITZ JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al
    Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  116. BASILI S, Proietti M, Perticone F, Corazza GR, et al
    Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study.
    Thromb Haemost. 2015;114.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Venous Thrombosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: